Antibiotics

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.

An analysis of the actions taken to combat antimicrobial resistance in 114 countries finds national action plans easier to develop than to implement.

It's Friday the 13th, but you can counteract bad luck by catching up on this week's top infectious disease news.

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

It's your day, pharmacists! Here's a roundup of our top 5 stories by infectious disease pharmacists, for infectious disease pharmacists.

In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.

A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.

Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.

In this mini-podcast, infectious diseases clinical pharmacy specialist Bruce M. Jones, PharmD, FIDSA, BCPS, breaks down the “very straightforward criteria” he uses to decide whether a skin and soft tissue infection (SSTI) patient should be inpatient or outpatient.

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.

In this podcast episode, Christian Sandrock, MD, MPH, FCCP, describes the need to make significant progress in antimicrobial stewardship.

It was a week marked by significant FDA decisions and COVID-19 treatment updates.

Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.

A clinician offers insight into what he sees in terms of these therapies and the need to get more information to those providers in the field as well as access to them.

COVID-19 hospital patients were prescribed 21.81% more antibiotics than patients without COVID-19. How did this affect their risk of coinfection?

With the proliferation of therapies for skin and soft tissue infections (SSTIs), a clinician discusses how providers can appropriately find the balance between these novel therapies, the existing treatment guidelines, and stewardship.

A clinician has a novel approach to patient conversations around this topic to determine if they want to assess if their penicillin allergies truly present a problem for treatment.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.

The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.